---
title: "Cerebrolysin"
canonical_url: https://peptidelibrary.app/library/cerebrolysin
description: "Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Cerebrolysin

Cerebrolysin (also called FPE 1070 or Porcine brain hydrolysate) is a peptide hydrolysate in the Neurotrophic peptide complex class. Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.

Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be.

Also known as: FPE 1070, Porcine brain hydrolysate.

Categories: Cognitive, Experimental.

## Classification

- Type: Peptide hydrolysate / nootropic research
- Mechanism class: Neurotrophic peptide complex
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.

Targets: Neuronal survival pathways, Neurotrophic signaling.

Origin: Enzymatic hydrolysate of porcine brain proteins.

## Properties

- Molecular weight: Mixture of low-MW peptides
- CAS number: 12656-49-6
- Half-life: Mixture; component PK not a single value
- Studied routes: Intravenous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 2
- Controlled human trials: 2
- Preclinical sources: 0
- Latest source: 2016

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012. 2012. Controlled human trial. Population: Adults with acute ischaemic hemispheric stroke, treated within 12 hours of onset (n=1,070). No significant difference on the combined primary endpoint (modified Rankin Scale, Barthel Index, NIHSS) [Source](https://pubmed.ncbi.nlm.nih.gov/22282884/)
2. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016. 2016. Controlled human trial. Population: Adults in early rehabilitation after stroke, treated from 24–72 hours after onset. Action Research Arm Test score at day 90 favoured cerebrolysin; the authors called the study exploratory [Source](https://pubmed.ncbi.nlm.nih.gov/26564102/)

## Safety

Side effects: Injection reactions; Agitation; Headache; Rare hypersensitivity.

Risks: Biological product variability; Not FDA-approved.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Cerebrolysin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Cerebrolysin?

Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be.

### How does Cerebrolysin work?

Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.

### Is Cerebrolysin FDA approved?

No. Cerebrolysin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Cerebrolysin?

Reported half-life for Cerebrolysin is Mixture; component PK not a single value. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What peptides are similar to Cerebrolysin?

Compounds most often compared with Cerebrolysin include Semax, N-Acetyl Semax Amidate, Adamax and Selank. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2023](https://pubmed.ncbi.nlm.nih.gov/37818733/)
- [Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials — Neurol Sci, 2017](https://pubmed.ncbi.nlm.nih.gov/28707130/)
- [Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2015](https://pubmed.ncbi.nlm.nih.gov/26083192/)
- [Cerebrolysin for vascular dementia — Cochrane Database Syst Rev, 2013](https://pubmed.ncbi.nlm.nih.gov/23440834/)
- [The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts — Neuroscience, 2025](https://pubmed.ncbi.nlm.nih.gov/39832667/)
